N-Acetylcysteine: Effects on the Liver and Kidneys

N-acetylcysteine, better known as NAC, sits at an unusual crossroads: it is an emergency-room antidote, a prescription mucolytic, and a widely used dietary supplement. Among athletes and people concerned about organ health, it is often promoted as a "liver and kidney protector." Our editorial team examined what the evidence really supports and where the claims go beyond the data.

What NAC is and how it works

NAC is an acetylated form of the amino acid cysteine. The acetyl group makes the molecule more stable and better absorbed than cysteine alone. Once in the body, NAC is deacetylated and supplies cysteine, which is often the rate-limiting building block for glutathione, the main intracellular antioxidant.

Glutathione neutralizes reactive oxygen species and conjugates many toxic compounds so they can be excreted. The liver contains particularly high concentrations because it handles most drug and toxin metabolism. When glutathione stores are depleted, liver cells become vulnerable to injury.

NAC also has direct antioxidant activity through its free thiol group and can break disulfide bonds in mucus proteins, which explains its use as a mucolytic. Additional effects on glutamate signaling have drawn interest in psychiatry, although those are outside the scope of this article.

Oral bioavailability of NAC is relatively low, estimated in pharmacokinetic studies at well under 10% for the intact molecule, because much of it is metabolized on first pass through the gut and liver. Paradoxically, this first-pass effect is part of why it works so well for the liver.

NAC and the liver: proven and possible roles

The best-established use of NAC is as the antidote for acetaminophen (paracetamol) overdose. Excess acetaminophen produces a toxic metabolite, NAPQI, which consumes glutathione and destroys liver cells. Given early enough, NAC restores glutathione and prevents severe liver failure. This use is standard in emergency medicine worldwide.

A landmark trial by Lee and colleagues tested intravenous NAC in non-acetaminophen acute liver failure. Overall survival did not differ significantly, but transplant-free survival improved in patients with early-stage coma. This suggests a potential benefit beyond acetaminophen, though under strict hospital conditions.

For chronic conditions such as non-alcoholic fatty liver disease, evidence comes mostly from animal studies and small human trials. Some report improvements in liver enzymes, but the data are too limited to recommend NAC as a treatment. No major hepatology guideline currently endorses it for fatty liver.

In sports settings, NAC is sometimes taken to "protect the liver" from oral anabolic steroids or other hepatotoxic substances. There is no clinical evidence that NAC prevents drug-induced liver injury from such agents, and relying on it can create a false sense of safety. The only reliable protection is avoiding the hepatotoxic exposure.

NAC and the kidneys: a story of mixed results

For years, NAC was given before imaging procedures with iodinated contrast to prevent contrast-associated kidney injury. Early small studies looked promising. However, the large randomized PRESERVE trial, published in 2018, found no benefit of oral NAC over placebo for preventing death, dialysis, or persistent kidney decline.

That result changed practice. Many guidelines no longer recommend NAC for contrast protection, emphasizing adequate hydration instead. The PRESERVE story is a classic example of how small positive studies can be overturned by well-designed large trials.

NAC can also lower serum creatinine slightly by mechanisms that may not reflect true kidney function. This complicates interpretation of some older studies, since creatinine was often the main outcome. Athletes should be aware that their own lab results can shift for reasons unrelated to organ health.

Regulatory status and use in the US

NAC has a complicated legal history in the United States. Because it was approved as a drug in 1963 before being marketed as a supplement, the FDA stated in 2020 that it did not meet the definition of a dietary supplement. After pushback from industry, the agency announced in 2022 that it would exercise enforcement discretion, and NAC supplements remain widely sold.

Prescription forms include inhaled solutions for respiratory use and intravenous and oral formulations for acetaminophen poisoning. Doses used in those settings are far higher than typical supplement doses and are given under medical supervision.

Supplement products commonly provide 600 mg per capsule, a dose used in many clinical studies of oral NAC. Labels and quality vary, so third-party testing is a sensible criterion when choosing a product.

Side effects and who should be careful

Oral NAC is generally well tolerated. The most common complaints are nausea, bloating, and diarrhea, along with a sulfur smell that many users find unpleasant. Intravenous NAC can cause anaphylactoid reactions, which is one reason it is administered in hospitals.

• People with asthma should be careful, as inhaled NAC can trigger bronchospasm.
• NAC may enhance the blood-pressure-lowering effect of nitroglycerin.
• Those with active peptic ulcers or bleeding disorders should consult a doctor first.
• Safety data for long-term high-dose use in healthy people are limited.

There is also an ongoing scientific debate about antioxidant supplementation and training. Some studies suggest that high doses of antioxidants can blunt certain adaptations to exercise. Evidence is not conclusive for NAC specifically, but it is a reason not to take it reflexively every day.

Conclusions of the editorial team

NAC is a genuinely valuable drug for acetaminophen poisoning and a reasonable option in some hospital cases of acute liver failure.

Its role in kidney protection has not held up in large trials, and its benefit for chronic liver conditions remains unproven.

As a supplement, NAC is relatively safe, but it should not be treated as a shield that makes risky substances or practices acceptable.

You may also find it useful to read our articles on liver enzyme tests for athletes, on glutathione supplements, and on interpreting creatinine in muscular people.

References

1. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856–864.
2. Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med. 2018;378(7):603–614.
3. Prescott LF, Illingworth RN, Critchley JA, et al. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J. 1979;2(6198):1097–1100.
4. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. N Engl J Med. 1988;319(24):1557–1562.
5. Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther. 2014;141(2):150–159.
6. Borgström L, Kågedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol. 1986;31(2):217–222.